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Abstract 
We present the first reported case of acute endophthalmitis due to Rhizobium radiobacter 
after an intravitreal injection of ranibizumab for neovascular age-related macular 
degeneration. 
 
Introduction 
We present the first reported case of acute endophthalmitis due to Rhizobium 
radiobacter after an intravitreal injection of ranibizumab for neovascular age-related 
macular degeneration (AMD). 
Case Report 
A 78-year-old lady presented with a one day history of reduced vision, redness and pain in the 
right eye, seven days after an intravitreal injection of ranibizumab to her right eye for neovascular 
AMD. Her intravitreal injection had been performed following a standard protocol which included the 
use of a speculum, but 0.05% chlorhexidine (Medlock Medical Ltd, UK) rather than 5% povidone 
iodine had been instilled into the fornix for three minutes prior to injection, as she had been recorded 
as developing an ‘allergic reaction’ to iodine following previous use. 
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On examination, her visual acuity was hand movements, down from 20/80 pre-injection. She had 
circumcorneal injection, a 1-mm hypopyon, a moderate nuclear sclerotic cataract, 3+ vitreous haze 
and 3+ vitreous cells in the affected eye (fig. 1). A clinical diagnosis of acute exogenous 
endophthalmitis was made, and she underwent a standard management plan which included anterior 
chamber and vitreous needle taps, followed by an intravitreal injection of vancomycin 2 mg in 0.1 ml 
and amikacin 0.4 mg in 0.1 ml. She was discharged on topical dexamethasone and chloramphenicol 
and oral moxifloxacin [1]. Initial Gram stain did not reveal fungal infection, but she was not 
considered suitable for oral corticosteroids in view of her age and systemic comorbidities (poorly 
controlled hypertension and well controlled type two diabetes mellitus). At her 48-h review, her eye 
was pain-free and the hypopyon had resolved. 
Culture of the vitreous biopsy specimen revealed the Gram-negative organism Rhizobium 
radiobacter strain. Antibiotic sensitivity testing showed resistance to ceftazidime, but susceptibility to 
ciprofloxacin, amikacin and vancomycin. One month after the injection, her visual acuity had 
improved to 20/100, with no evidence of persistent inflammation. Three months after injection, her 
visual acuity remained at 20/100. 
Discussion 
The incidence of endophthalmitis cases after intravitreal anti-VEGF agents is 
estimated to be 0.049%, with most isolates being commensals such as coagulase-
negative Staphylococcus or Streptococcus viridans [2]. Rhizobium radiobacter has not 
previously been reported to be a causative organism following intravitreal injection, 
but its presentation appears no different from other causative organisms. However, its 
source in our patient is unclear, as it is an organism predominantly found in soil. A few 
cases have been reported in which it has caused both acute and chronic 
endophthalmitis following cataract surgery [3], and it was hypothesised in these cases 
that infection occurred as a result of conjunctival inoculation following patient contact 
with soil, but our patient reported no gardening activities following her intravitreal 
injection, suggesting that the organism was already present in the conjunctival sac. 
The use of chlorhexidine rather than povidone iodine prior to injection was based on 
a presumed allergy. However, this is more likely to have represented conjunctival 
irritation than a true allergy. Chlorhexidine 0.05% is as effective as 4% povidone iodine 
at reducing conjunctival flora in general [4], but there have been concerns that some 
organisms may be resistant to chlorhexidine [5]. However, this remains controversial, 
and meta-analysis of its use in other surgical situations has suggested it to be superior 
to povidone iodine [6]. It is possible that resistance to chlorhexidine might be acquired 
in certain situations [7], but this patient had previously received only povidone iodine. 
Lower concentrations of povidone iodine, e.g. 1%, can be used to reduce irritation in 
susceptible patients, but are considered less effective in patients with higher initial 
conjunctival bacterial loads [8]. 
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Fig. 1. The patient presented with a clinical picture consistent with endophthalmitis, consisting of a 
red, painful eye together with a 1-mm hypopyon and vitreous haze and cells. 
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